Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
The WHO on Tuesday continued to express confidence in the H1N1 (swine flu) vaccine as few mild adverse effects have been reported by patients participating in China's vaccine campaign, the Associated Press reports. Out of the 39,000 people in China who received the H1N1 vaccine, four reported experiencing side effects such as muscle cramps and headache, according to WHO spokesman Gregory Hartl (Higgins, 10/6).
In keeping with the global effort to limit the spread of the Swine Flu, the California Dental Hygienists’ Association (CDHA) issued a list today of simple ways patients and oral health professionals can prevent catching and spreading the disease.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
With the current H1N1 flu (swine flu) pandemic under way, many public health officials are concerned that critical healthcare resources could be stretched thin as people flood hospital emergency departments and physicians' offices to determine whether they have the illness.
Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
A new report out yesterday places autism rates among U.S. children at one in 91, with autism now affecting one in 58 boys. These new numbers, from Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, are prompting outrage from parents and autism advocates over inaction from government health agencies in addressing the crisis affecting hundreds of thousands of American families.
The first doses of Swine Flu have arrived in the United States, as health officials work quickly to inoculate people against the virus.
In President Obama's Washington, medical specialists are slightly more popular than the H1N1 virus. … [T]he quiet war Democrats are waging on specialists is astonishing (10/6).
Jose Angel Cordova Villalobos, Secretary of Health, United States of Mexico, discussed preparations and responses to the H1N1 influenza during a visit to Washington D.C.
Minnesota's physicians are urging parents to watch for the warning signs that their child is having a severe case of H1N1 and to seek out the H1N1 vaccine for their child when it becomes available.
Besides insurance coverage, several others factors such as racial differences, zip code, education level and income, have an even bigger effect on health.
Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.
The number of H1N1 (swine flu) cases reported in WHO regions worldwide has grown by at least 24,000 in two weeks to cross the 340,000 mark since the virus was first detected in mid-April, the CDC reported Monday, according to Agence France-Presse.
Memorial Blood Centers today outlined steps the organization is taking to stay prepared for the spread of the H1N1 virus and to ensure a safe experience for blood donors and an ample blood supply for our communities.
With the first doses of the H1N1 (swine) flu vaccine being shipped and seasonal flu shots underway, people should be getting vaccinations when they can for these flu viruses, said Sharon Stanley, Chief Nurse of the American Red Cross.
Catalent Pharma Solutions announces that its commercial packaging facility in Corby, United Kingdom, received a High Commendation recognition in the Judge’s Special Award category, in the recently announced “2009 Best Factory Awards.” The Corby facility was nominated in several categories, including “Best Process Factory” and “Overall Best UK Factory.”
With fall allergy season underway and Americans concerned about keeping their family safe from H1N1 and other flu viruses, health educator and fitness trainer Isabella "Betti" Jones is urging Americans to take a proactive, natural approach to staying healthy - the important step of daily sinus cleansing.
Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.
This fall the CDC estimates that upwards of 50 percent of Americans could come down with the H1N1 virus, killing as many as 1.2 million people. Additionally, there are estimates that many companies will experience between 30-50 percent absenteeism due to employee illness.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.